Medicare GLP-1 Coverage 2026: The Bridge Program Explained

Quick Answer

Coverage depends on the prescription's purpose, eligible Part D enrollment, and the clinical criteria below. No beneficiary registration is required, but coverage is not automatic. The pharmacy must submit a Bridge claim before the prescriber submits the required prior authorization.[1]

For appointment preparation and first-fill troubleshooting, use our step-by-step $50 coverage checklist.

How the Program Works

CMS uses a central processor in 2026 to handle Bridge prior authorizations, claims, and pharmacy payments. Part D sponsors do not have to opt in; pharmacies do not have to opt in either. The program is nationwide, including U.S. territories.[1][2]

Current CMS Resources

• Provider guidance and prior authorization resources
• Pharmacy guidance, covered NDCs, and billing resources

Part D and the Bridge Are Different

CMS directs prescriptions for a Part D-covered indication to the beneficiary's Part D plan. This includes relevant diagnoses beyond diabetes; Medicare GLP-1 coverage is not simply “diabetes covered, everything else excluded.” Product indications and plan authorization requirements still matter.[1]

Which GLP-1 Drugs Are Covered

CMS lists the following products for eligible weight-management use. Check the current CMS National Drug Code (NDC) list because it may change.[1]

Foundayo is orforglipron, not cagrilintide/semaglutide. Its prescribing information identifies it as an oral GLP-1 receptor agonist. Coverage guides are not a substitute for product-specific prescribing instructions.[5]

CMS says pen needles for Zepbound KwikPen are not covered by the Bridge and should not be billed to the patient's Part D plan. Ask the pharmacy about this separate expense.[2]

Who Qualifies: Clinical Criteria

Eligible Enrollment

Eligible enrollment includes a standalone prescription drug plan (PDP), a Medicare Advantage coordinated care plan with drug coverage (HMO, HMOPOS, or local/regional PPO), Special Needs Plans, employer/union group waiver plans, and LI NET. People with both Medicare and Medicaid may qualify.[1]

Private fee-for-service plans, section 1876 cost contract plans, section 1833 health care prepayment plans, PACE, fallback plans, and religious fraternal benefit plans are excluded unless the person also has a standalone PDP, as applicable. If uncertain, ask your plan, 1-800-MEDICARE, or your State Health Insurance Assistance Program (SHIP) about your enrollment; the Bridge itself is not a Part D plan.[1]

BMI and Qualifying Conditions

CMS requires age 18 or older and a prescription to reduce excess weight and maintain weight reduction, with ongoing structured nutrition and physical activity consistent with the FDA-approved label. The prescriber must attest to one of these pathways, using BMI and qualifying conditions at initiation of GLP-1 therapy:[1]

These are specific CMS criteria—not “any weight-related condition.” The initiation rule also applies to people who began treatment before Medicare enrollment or before July 1, 2026. Bring older clinical records if available; do not assume that a lower current BMI rules you out.[1]

Diagnoses and Prescribing Purpose

CMS excludes beneficiaries with type 2 diabetes, moderate-to-severe obstructive sleep apnea, or the relevant noncirrhotic MASH diagnosis because these indications have a Part D coverage route. The provider FAQ clarifies the MASH diagnosis as involving moderate-to-advanced liver scarring consistent with F2–F3 fibrosis. Prescribers must assess the actual diagnoses accurately; good control on treatment does not automatically mean a diagnosis no longer applies.[1]

Cardiovascular disease needs a separate distinction: prior heart attack, stroke, or symptomatic peripheral artery disease can meet the Bridge's BMI ≥27 pathway for weight management. But a prescription intended to reduce major cardiovascular events goes to Part D, even if weight management is also a goal. Part D eligibility for an indication does not guarantee every product is covered; check the plan's formulary and authorization rules.[1]

How to Access the Bridge

1. Discuss suitability and coverage with the prescriber. Bring your medication list, Medicare and plan details, and records of BMI and diagnoses at GLP-1 therapy initiation.
2. The prescriber sends the prescription to the pharmacy. CMS recommends a diagnosis code and routing annotation where appropriate, but does not require them. A Part D denial is not required first.[1]
3. The pharmacy submits a Bridge claim. This must establish eligibility before prescriber prior authorization. Reversing the order can produce a “patient not found” error.[1]
4. The pharmacy requests authorization from the prescriber. CMS says this normally happens electronically or by fax within 24–72 hours. If the request has not arrived after 72 hours, the prescriber can use the fax form linked from the CMS provider page, after the claim step.[1]
5. The prescriber submits the clinical attestation. CMS says an approval or denial is sent to the prescriber within 72 hours of submission and mailed to the patient. The pharmacy may need to resubmit the claim once approved.[1][2]

The prescriber call center is 855-273-0102 (Monday–Friday, 8 a.m.–7 p.m. Eastern); the pharmacy help desk is 844-673-0910. An authorization request is not guaranteed approval. CMS permits resubmission with corrected or additional information but says there is no Bridge appeals process.[1][2]

What the $50 Copay Means for Your Costs

The copay is $50 for a single monthly supply of 28 or 30 days. CMS says partial, 60-day, and 90-day fills are not available.[2]

• The Part D deductible does not apply.
• The $50 does not count toward Part D TrOOP, or true out-of-pocket spending.
• Extra Help does not reduce the copay. There is no low-income subsidy for Bridge prescriptions.
• Coupons and discount programs cannot be applied, regardless of funding source; the Bridge does not coordinate benefits with other payers.
• No direct member reimbursement: do not pay cash expecting a later Bridge refund.[2]

This is the prescription copay, not a promise that visits, monitoring, or injection supplies are free. Confirm other charges with the relevant provider or pharmacy.

Refills and Changes in Eligibility

CMS says prior authorizations last through December 31, 2027, with a new authorization needed if switching to a different covered GLP-1 drug. An approval does not override later ineligibility: a subsequent GLP-1 fill under Part D or moving to an excluded plan type can cause a Bridge refill rejection.[2]

The pharmacy can process a vacation override at the point of sale, but CMS does not offer lost- or stolen-medication overrides. Contact the pharmacy before travel or if a refill is rejected rather than changing treatment on your own.[2]

What the Bridge Does Not Do

• It does not cover every beneficiary or every GLP-1 product.[1]
• It does not replace Part D for prescriptions intended for Part D-covered indications.[1]
• It does not make the $50 count toward Part D spending or allow Extra Help to reduce that copay.[2]
• It does not guarantee permanent coverage after December 31, 2027.[1]

What Happens When the Bridge Ends

CMS says the extension through December 31, 2027 allows additional data collection ahead of potential BALANCE implementation in Part D. BALANCE is not launching in 2027. The guidance does not promise permanent coverage, an income-based copay, or a confirmed successor launch date.[1]

Discuss continuity of care before a coverage change. Do not assume that switching Medicare Advantage plans, using a manufacturer assistance program, or purchasing a compounded product guarantees an equivalent covered option. Confirm actual benefits and clinical suitability with the care team rather than acting on a predicted policy change.

Bottom Line

The Bridge offers eligible beneficiaries a separate $50 monthly prescription benefit, but requires the right plan type, clinical criteria, and a pharmacy-first authorization process. Use the step-by-step checklist to prepare for the first fill. Older adults and caregivers can also review GLP-1 safety for seniors.

This article is informational, not medical or insurance advice. CMS guidance was checked September 13, 2026. Verify the current rules and your specific prescription with your prescriber, pharmacy, and Medicare plan.

Sources

• [1] cms.gov
• [2] cms.gov
• [5] pi.lilly.com